Tesamorelin

Tesamorelin is a synthetic growth-hormone-releasing-factor analogue studied in pituitary GH release, IGF-1 signaling, body-composition research, and metabolic effects.

Activates pituitary GHRH receptors, increasing endogenous growth-hormone secretion and downstream IGF-1.

Substantial human evidence and an FDA-approved prescription drug for a specific indication.

Review required

Approved-product evidence does not establish equivalence of an independently sourced research preparation.

Approved labeling includes glucose intolerance, elevated IGF-1, fluid retention, hypersensitivity, injection-site reactions, and contraindications related to active malignancy or disrupted hypothalamic-pituitary axis.

The active ingredient is used in an FDA-approved prescription drug; research material is not an approved product.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

• Tesamorelin, 5 mgLyophilized
• Tesamorelin, 10 mgLyophilized

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.